The product Oxandrolone (10 mg per tablet), manufactured by Optitropin, was submitted for independent testing by individual B Ware. The sample was analyzed by Janoshik Analytical to verify its potency. The results indicate that the sample contained 10.36 mg and 10.08 mg of Oxandrolone per tablet in separate tests, which represents 103.6% and 100.8%, respectively, of the labeled claim of 10 mg.
Testing was initiated on 5 January 2024, with the sample received on 11 January 2024, and the analysis was conducted on the same day. The measured concentrations are slightly above the labeled dose but remain within an acceptable pharmaceutical variance, indicating strong quality control for this batch.
This report is published to promote transparency and harm reduction, helping consumers make informed decisions regarding pharmaceutical product use.
Detailed Report
Product Overview
- Manufacturer: Optitropin
- Product Name: Oxandrolone
- Active Ingredient: Oxandrolone
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Oral Tablet
Sample Acquisition and Testing
- Task Number: #37371
- Testing Ordered: 5 January 2024
- Sample Received: 11 January 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: B Ware (Individual)
- Analysis Paid For By: B Ware (Individual)
Testing Results
| Specification | Measured Concentration | Accuracy | Variance |
|---|---|---|---|
| 10 mg (as per label) | 10.36 mg | 103.6% | +3.6% |
| 10 mg (as per label) | 10.08 mg | 100.8% | +0.8% |
Verification Details
- Verification URL: https://janoshik.com/tests/37371_5VYMVJQXFN89
Evaluation of Individual-Submitted Testing
The analysis confirms that the Oxandrolone (10 mg per tablet) sample meets and slightly exceeds its labeled claim in separate tests (103.6% and 100.8% of the label claim). This minor overage is within acceptable pharmaceutical tolerances, suggesting high-quality manufacturing standards for this batch.
Since the sample was submitted by B Ware, an individual consumer with no commercial ties, there is no potential bias from reseller or manufacturer submissions. However, as with any single-batch test, additional independent testing across multiple batches is advised to validate the consistency of the entire product line.
Conclusion
The results confirm that Optitropin’s Oxandrolone (10 mg) met or slightly exceeded its labeled potency, with measured concentrations of 10.36 mg and 10.08 mg per tablet. This reflects strong quality control for the tested batch, but regular third-party testing is recommended to ensure batch-to-batch consistency.
This report is provided to educate consumers and support harm reduction by facilitating informed decision-making regarding pharmaceutical products.
Disclaimer
This report is for educational and harm reduction purposes only. The results pertain solely to the batch tested and may not reflect the quality of other batches. Although B Ware has no commercial interests, readers are encouraged to critically assess this information alongside third-party or independent data to form a comprehensive understanding of product consistency. Always consult healthcare professionals and adhere to local regulations before using such products.
